ArticleOncology letters2025
Effects of SB939 are mediated by STAT3 to inhibit breast cancer cell metastasis-related genes.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The histone deacetylase inhibitor pracinostat (SB939) may inhibit metastasis of triple-negative breast cancer by downregulating fibronectin (FN1) expression through the STAT3 signaling pathway. SB939 exhibits low cytotoxicity and is a potential targeted agent against breast cancer. The present study investigated the value of STAT3 and FN1 as breast cancer treatment targets and integrated cancer databases and bioinformatics tools to evaluate the effect of SB939 on breast cancer metastasis. Gene Set Enrichment Analysis, Gene Expression Profiling Interactive Analysis, Gene Expression Database of Normal and Tumor Tissues 2, The University of Alabama at Birmingham Cancer data analysis portal, GeneMANIA, Search Tool for the Retrieval of Interacting Genes/Proteins, LinkedOmics and Tumor Immune Estimation Resource databases were used in the present study. SB939 inhibited enrichment of the STAT3 pathway and decreased the expression of FN1. FN1 and STAT3 expression was markedly higher in breast cancer tissues compared with normal tissues. Kaplan-Meier curves demonstrated that increased expression of STAT3 and FN1 was associated with low survival in patients with breast cancer with overall, recurrence-free and disease-specific survival and FN1 having the strongest association with MMP2, which facilitating extracellular matrix degradation and metastatic niche formation. Furthermore, MMP2 exhibits crosstalk STAT3 to induce metastasis of breast cancer cells. To conclude, SB939 may be used as a small molecule compound for the clinical treatment of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.